



Diagnostics Biochem Canada Inc.

Manufacturer of In Vitro Diagnostic Test Kits Since 1973

**ELISA Kit...The EiAsy™ Way
ANDROSTENEDIONE SALIVA**

Cat. No.: CAN-AD-220

Version: 4.0

Effective: October 15, 2003

INTENDED USE

For the quantitative determination of Androstenedione by enzyme immunoassay in human saliva.

For *in vitro* use only.

PRINCIPLE OF THE TEST

The principle of the following enzyme immunoassay test follows the typical competitive binding scenario. Competition occurs between an unlabeled antigen (present in standards, control and patient samples) and an enzyme-labelled antigen (conjugate) for a limited number of antibody binding sites on the microwell plate. The washing and decanting procedures remove unbound materials. After the washing step, the enzyme substrate is added. The enzymatic reaction is terminated by addition of the stopping solution. The absorbance is measured on a microtiter plate reader. The intensity of the colour formed is inversely proportional to the concentration of androstenedione in the sample. A set of standards is used to plot a standard curve from which the amount of androstenedione in patient samples and controls can be directly read.

CLINICAL APPLICATIONS

Androstenedione, a major androgen found in peripheral blood, is secreted by the ovary, testis and the adrenal gland. Androstenedione is the immediate precursor to testosterone in the biosynthetic pathway. A significant percentage of secreted androstenedione is converted peripherally, principally to testosterone.

Androstenedione is increased in a high percentage of women with polycystic ovarian syndrome (PCO), hirsutism, various signs of hyperandrogenicity, tumors of the adrenal gland, and congenital adrenal hyperplasia (CAH). Information on the concentration of androstenedione might also be of interest in some of the reproductive system disorders such as sexual precocity, female phenotype at birth, or sexual ambiguity. The correlation has been found between salivary androstenedione and plasma total androstenedione. Salivary levels of androstenedione were also found to be approximately equal to and highly correlated with the free plasma level. As a result, the determination of salivary androstenedione combines a highly sensitive technique and non-invasive sample collection that is of value in clinical and research studies.

PROCEDURAL CAUTIONS AND WARNINGS

1. Users should have a thorough understanding of this protocol for the successful use of this kit. Reliable performance will only be attained by strict and careful adherence to the instructions provided.
2. Control materials should be included in every run at a high and low level for assessing the reliability of results.
3. When the use of water is specified for dilution or reconstitution, use deionized or distilled water.
4. In order to reduce exposure to potentially harmful substances, gloves should be worn when handling kit reagents and human specimens.

5. All kit reagents and specimens should be brought to room temperature and mixed gently but thoroughly before use. Avoid repeated freezing and thawing of reagents and specimens.
6. A calibrator curve must be established for every run.
7. The control should be included in every run and fall within established confidence limits.
8. Improper procedural techniques, imprecise pipetting, incomplete washing as well as improper reagent storage may be indicated when assay values for the control do not reflect established ranges.
9. When reading the microplate, the presence of bubbles in the microwells will affect the optical densities (ODs). Carefully remove any bubbles before performing the reading step.
10. The substrate solution (TMB) is sensitive to light and should remain colourless if properly stored. Instability or contamination may be indicated by the development of a blue colour, in which case it should not be used.
11. When dispensing the substrate and stopping solution, do not use pipettes in which these liquids will come into contact with any metal parts.
12. To prevent contamination of reagents, use a new disposable pipette tip for dispensing each reagent, sample, standard and control.
13. Do not mix various lot numbers of kit components within a test and do not use any component beyond the expiration date printed on the label.
14. Kit reagents must be regarded as hazardous waste and disposed of according to national regulations.

LIMITATIONS

1. All the reagents within the kit are calibrated for the direct determination of androstenedione in human saliva. The kit is not calibrated for the determination of androstenedione in serum, plasma or other specimens of human or animal origin.
2. Any samples or control sera containing azide or thimerosal are not compatible with this kit, as they may lead to false results.
3. Only calibrator A may be used to dilute any high saliva samples. The use of any other reagent may lead to false results.
4. The results obtained with this kit should never be used as the sole basis for a clinical diagnosis. For example, the occurrence of heterophilic antibodies in patients regularly exposed to animals or animal products has the potential of causing interferences in immunological tests. Consequently, the clinical diagnosis should include all aspects of a patient's background including the frequency of exposure to animals/products if false results are suspected.

**SAFETY CAUTIONS AND WARNINGS
POTENTIAL BIOHAZARDOUS MATERIAL**

Human serum that may be used in the preparation of the standards and control has been tested and found to be non-reactive for Hepatitis B surface antigen and has also been tested for the presence of antibodies to HCV and Human Immunodeficiency Virus (HIV) and found to be negative. However no test method can offer complete assurance that HIV, HCV and Hepatitis B virus or any infectious agents are absent. The reagents should be considered a potential biohazard and handled with the same precautions as applied to any blood specimen.

CHEMICAL HAZARDS

Avoid contact with reagents containing TMB, hydrogen peroxide and sulfuric acid. If contacted with any of these reagents, wash with plenty of water. TMB is a suspected carcinogen.

SPECIMEN COLLECTION AND STORAGE

Approximately 1 ml of saliva is required per duplicate determination. Collect 4-5 ml of saliva into a clean glass tube without force or indcement and before eating, drinking or brushing the teeth. Simply rinse the mouth with water before collection. Do not use blood-contaminated specimens. Store samples at 4°C for up to 24 hours or at -10°C or lower if the analyses are to be done at a later date. Consider all human specimens as possible biohazardous materials and take appropriate precautions when handling.

SPECIMEN PRETREATMENT

Specimen tubes are to be placed into a freezer and allowed to freeze. When ready to use, the specimens are to be thawed and centrifuged. The supernatants are to be collected and poured into freshly labelled tubes.

REAGENTS AND EQUIPMENT NEEDED BUT NOT PROVIDED

1. Precision pipettes to dispense 50, 100 and 300 µl
2. Disposable pipette tips
3. Distilled or deionized water
4. Plate shaker
5. Benchtop centrifuge
6. Microwell plate reader with a filter set at 450nm and an upper OD limit of 3.0 or greater* (see assay procedure step 10).

REAGENTS PROVIDED

1. Rabbit Anti-Androstenedione Antibody Coated Microwell Plate-Break Apart Wells - Ready To Use.

Contents: One 96 well (12x8) polyclonal antibody-coated microwell plate in a resealable pouch with desiccant.
Storage: Refrigerate at 2-8°C
Stability: 12 months or as indicated on label.

2. Androstenedione-Horseradish Peroxidase (HRP) Conjugate Concentrate - Requires Preparation.

Contents: Androstenedione-HRP conjugate in a protein-based buffer with a non-mercury preservative.
Volume: 800 µl/vial
Storage: Refrigerate at 2-8°C
Stability: 12 months or as indicated on label.
Preparation: Dilute 1:20 in assay buffer before use (eg. 100 µl of HRP in 2 ml of assay buffer). If the whole plate is to be used dilute 600 µl of HRP in 12ml of assay buffer. Discard any that is left over.

3. Androstenedione Saliva Calibrators - Ready To Use.

Contents: Six vials containing androstenedione in a protein-based buffer with a non-mercury preservative. Prepared by spiking buffer with a defined quantity of androstenedione.
*Listed below are approximate concentrations, please refer to vial labels for exact concentrations.

Calibrator	Concentration	Volume/Vial
Calibrator A	0 pg/ml	3.0 ml
Calibrator B	5 pg/ml	1.0 ml
Calibrator C	20 pg/ml	1.0 ml
Calibrator D	100 pg/ml	1.0 ml
Calibrator E	300 pg/ml	1.0 ml
Calibrator F	1000 pg/ml	1.0 ml

Storage: Refrigerate at 2-8°C

Stability: 12 months in unopened vials or as indicated on label. Once opened, the standards should be used within 14 days or aliquoted and stored frozen. Avoid multiple freezing and thawing cycles.

4. Control - Ready To Use.

Contents: One vial containing androstenedione in a protein-based buffer with a non-mercury preservative. Prepared by spiking buffer with a defined quantity of androstenedione. Refer to vial label for expected value and acceptable range.
Volume: 1.0 ml/vial
Storage: Refrigerate at 2-8°C
Stability: 12 months in unopened vial or as indicated on label. Once opened, the control should be used within 14 days or aliquoted and stored frozen. Avoid multiple freezing and thawing cycles.

5. Wash Buffer Concentrate - Requires Preparation.

Contents: One bottle containing buffer with a non-ionic detergent and a non-mercury preservative.
Volume: 50 ml/bottle
Storage: Refrigerate at 2-8°C
Stability: 12 months or as indicated on label.
Preparation: Dilute 1:10 in distilled or deionized water before use. If the whole plate is to be used dilute 50 ml of the wash buffer concentrate in 450 ml of water.

6. Assay Buffer - Ready To Use.

Contents: One vial containing a protein-based buffer with a non-mercury preservative.
Volume: 15 ml/vial
Storage: Refrigerate at 2-8°C
Stability: 12 months or as indicated on label.

7. TMB Substrate - Ready To Use.

Contents: One bottle containing tetramethylbenzidine and hydrogen peroxide in a non-DMF or DMSO containing buffer.
Volume: 16 ml/bottle
Storage: Refrigerate at 2-8°C
Stability: 12 months or as indicated on label.

8. Stopping Solution - Ready To Use.

Contents: One vial containing 1M sulfuric acid.
Volume: 6 ml/vial
Storage: Refrigerate at 2-8°C
Stability: 12 months or as indicated on label.

ASSAY PROCEDURE

Specimen Pretreatment:
Freezing and Centrifugation.

All reagents must reach room temperature before use. Calibrators, controls and specimen samples should be assayed in duplicate. Once the procedure has been started, all steps should be completed without interruption.

1. Prepare working solutions of the androstenedione-HRP conjugate and wash buffer.
2. Remove the required number of microwell strips. Reseal the bag and return any unused strips to the refrigerator.
3. Pipette 100 µl of each calibrator, control and specimen sample into correspondingly labelled wells in duplicate.
4. Pipette 100 µl of the conjugate working solution into each well (We recommend using a multichannel pipette).
5. Incubate on a plate shaker (approximately 200 rpm) for 1 hour at room temperature.
6. Wash the wells 3 times with 300 µl of diluted wash buffer per well and tap the plate firmly against absorbent paper to ensure that it is dry (The use of a washer is recommended).
7. Pipette 100 µl of TMB substrate into each well at timed intervals.
8. Incubate on a plate shaker for 10-15 minutes at room temperature (or until calibrator A attains dark blue colour for desired OD).
9. Pipette 50 µl of stopping solution into each well at the same timed intervals as in step 7.
10. Read the plate on a microwell plate reader at 450nm within 20 minutes after addition of the stopping solution.

* If the OD exceeds the upper limit of detection or if a 450nm filter is unavailable, a 405 or 415nm filter may be substituted. The optical densities will be lower, however, this will not affect the results of patient/control samples.

CALCULATIONS


1. Calculate the mean optical density of each calibrator duplicate.
2. Draw a calibrator curve on semi-log paper with the mean optical densities on the Y-axis and the calibrator concentrations on the X-axis. If immunoassay software is being used, a 4-parameter curve is recommended.
3. Calculate the mean optical density of each unknown duplicate.
4. Read the values of the unknowns directly off the calibrator curve.
5. If a sample reads more than 1000 pg/ml then dilute it with calibrator A at a dilution of no more than 1:8. The result obtained should be multiplied by the dilution factor.

TYPICAL TABULATED DATA

Calibrator	OD 1	OD 2	Mean OD	Value (pg/ml)
A	2.985	2.868	2.917	0
B	2.590	2.546	2.568	5
C	2.220	2.192	2.206	20
D	0.837	0.852	0.845	100
E	0.357	0.332	0.345	300
F	0.151	0.149	0.150	1000
Unknown	0.637	0.665	0.651	134

TYPICAL CALIBRATOR CURVE

Sample curve only. **Do not** use to calculate results.

**PERFORMANCE CHARACTERISTICS****SENSITIVITY**

The lower detection limit is calculated from the standard curve by determining the resulting concentration of the mean OD of Calibrator A (based on 10 replicate analyses) minus 2 SD. Therefore, the sensitivity of the dbc Androstenedione Saliva ELISA kit is **1.0 pg/ml**.

SPECIFICITY (CROSS REACTIVITY)

The following compounds were tested for cross-reactivity with the Androstenedione Saliva ELISA kit with androstenedione cross-reacting at 100%.

Steroid	%Cross Reactivity
Androstenedione	100
Androstandione	2.79
Testosterone	0.2
Dihydrotestosterone	0.1
Epiandrosterone	0.1

The following steroids were tested but cross-reacted at less than 0.1%: Androstenedione Sulfate, Androsterone, Cortisol, Dehydroisoandrosterone, Dehydroepiandrosterone Sulfate, Dihydroandrosterone, 5β-Dihydrotestosterone, 17β-Estradiol, Estrone, Etiocholanolone Glucuronide and Progesterone.

INTRA-ASSAY PRECISION

Three samples were assayed ten times each on the same calibrator curve. The results (in pg/ml) are tabulated below:

Sample	Mean	SD	CV%
1	47.57	1.64	3.4
2	58.48	1.61	2.8
3	134.37	5.24	3.9

INTER-ASSAY PRECISION

Three samples were assayed ten times over a period of four weeks. The results (in pg/ml) are tabulated below:

Sample	Mean	SD	CV%
1	37.81	2.18	5.8
2	116.00	6.32	5.4
3	153.46	8.40	5.5

RECOVERY

Spiked samples were prepared by adding defined amounts of androstenedione to four patient saliva samples. The results (in pg/ml) are tabulated below:

Sample	Obs.Result	Exp.Result	Recovery%
1 Unspiked	34.3	-	-
+ 100	130.20	134.3	96.9
2 Unspiked	51.7	-	-
+ 20	69.9	71.7	97.5
+ 60	93.5	111.7	83.7
+ 200	238.5	251.7	94.8
3 Unspiked	99.0	-	-
+ 200	337.8	299.0	91.8
4 Unspiked	110.4	-	-
+ 400	501.1	510.4	98.2

LINEARITY

Three patient saliva samples were diluted with calibrator A. The results (in pg/ml) are tabulated below:

Sample	Obs.Result	Exp.Result	Recovery%
1	130.2	-	-
1:2	74.98	65.1	115.2
1:4	34.31	32.6	105.2
1:8	19.78	16.3	121.3
2	337.8	-	-
1:2	155.17	168.9	91.9
1:4	104.80	84.5	124.0
1:8	51.60	42.2	122.3
3	500.2	-	-
1:2	247.2	250.1	98.6
1:4	137.6	125.3	109.8
1:8	76.2	62.6	120.6

EXPECTED NORMAL VALUES

As for all clinical assays each laboratory should collect data and establish their own range of expected normal values.

Group	N	Range (pg/ml)
Males	28	48-309
Females	23	32-330

EXTRACTION VS. NON-EXTRACTION COMPARITIVE STUDY

The dbc Androstenedione Saliva ELISA method was validated by the following comparative study between:

1. Direct assay of saliva samples
2. Prior extraction of saliva samples with diethyl ether
3. Prior heating of saliva samples for 1 hour at 60-70°C

The results (in pg/ml) are tabulated below:

Sample	Direct	Extracted	Heated
1	17	20	19
2	65	63	59
3	45	33	43
4	45	38	52
5	51	42	55
6	38	31	42
7	82	74	77
8	67	65	59
9	49	65	56
10	115	98	108

The data from these 10 random saliva samples show a strong agreement between all of the three methods. As a result, the direct method was chosen due to its easier and less time consuming technique.

REFERENCES

1. Berel, E., et al., J. Steroid Biochem. 13:89,1980.
2. Bermudez, J.A., et al., J. Steroid Biochem 6:283,1975.
3. Hampl, R., et al., J. Steroid Biochem 9:771, 1978.
4. Hummer, L., et al.,Scand.J.Clin.Lab.Invest.43:301,1983.
5. Hennam, J.F., et al., Acta Endocrinol.76:597, 1974.
6. Judd, H.L., et al., J. Clin. Endo. Metabo. 36:475, 1973.
7. Lejeune-Lenair, C., et al., Clin. Chem. Acta.94:327, 1979.
8. Parker, L.N., et al., Steroids 29:715, 1977.
9. Pizarro, M.A., et al., J. Steroid Biochem. 12:509, 1980.
10. Rao, PN., et al, Steroids 24:793,1974.
11. Putz, Z. et al., J. Clin.Chem.Clin.Biochem.20:761,1982.
12. Schandader, B.D., et al, Endocrinology 97:787, 1975.
13. Slaats, EH., et al., Clin. Chem. 33:300, 1987.
14. Swinkles, L.M., et al., Am. Clin. Biochem.23:354, 1988.
15. Swinkles, L.M., et al., Clin. Chem. 38:1819, 1992.
16. Thornycroft, I.H., et al., Steroids 21:111, 1973.
17. Besch, N.F., et al., Clin. Chem. 32:1357, 1986.
18. Check, J.H., et al., Falsely elevated steroidal assay levels related to heterophile antibodies against various animal species. Gynecol Obstet Invest 40:139-140,1995.

CONTACT INFORMATION

Diagnostics Biochem Canada Inc.
1020 Hargrieve Road
London, Ontario, Canada, N6E 1P5
Tel/Fax: (519) 681 8731, E-mail:dbc@dbc-labs.com
Internet: www.dbc-labs.com
ISO 9001:2000 and ISO 13485 Certified